@ecamp1234.bsky.social
🌟 Lover of arts, culture, coffee, music, books, travel. Amateur photographer. 📸☕️ 🎨
🌟 Enjoy dabbling in #ASX stocks. ✍️ Australia 🇦🇺
🌟 Enjoy dabbling in #ASX stocks. ✍️ Australia 🇦🇺
Thanks Tobias 🙏
September 21, 2025 at 6:32 AM
Thanks Tobias 🙏
Absolutely 🩵
September 20, 2025 at 11:56 AM
Absolutely 🩵
Thanks Kate 🙏
The National Parks & Wildlife Service actually installed a section of synthetic grass at the lookout to accommodate heavy use of the site for weddings and hang gliding. I suppose it was chosen over pavers for both safety and aesthetic reasons. 🌸
The National Parks & Wildlife Service actually installed a section of synthetic grass at the lookout to accommodate heavy use of the site for weddings and hang gliding. I suppose it was chosen over pavers for both safety and aesthetic reasons. 🌸
September 15, 2025 at 11:21 AM
Thanks Kate 🙏
The National Parks & Wildlife Service actually installed a section of synthetic grass at the lookout to accommodate heavy use of the site for weddings and hang gliding. I suppose it was chosen over pavers for both safety and aesthetic reasons. 🌸
The National Parks & Wildlife Service actually installed a section of synthetic grass at the lookout to accommodate heavy use of the site for weddings and hang gliding. I suppose it was chosen over pavers for both safety and aesthetic reasons. 🌸
Thank you. 🙏
September 14, 2025 at 3:59 AM
Thank you. 🙏
Love his work, thanks for sharing Ann. 🙏
September 13, 2025 at 10:49 AM
Love his work, thanks for sharing Ann. 🙏
Hi Sam, hope you are well.
August 30, 2025 at 12:53 AM
Hi Sam, hope you are well.
Agree. Their current cash reserves and short term inflows are probably not sufficient to fund a global rollout of their system.
August 10, 2025 at 2:07 AM
Agree. Their current cash reserves and short term inflows are probably not sufficient to fund a global rollout of their system.
Positives:
• Strong recurring revenue potential.
Risks:
• Still early-stage commercialisation – revenue ramp dependent on successful evaluations converting to full rollouts.
• Pharma adoption cycles are LONG (12–24 mths from evaluation to rollout).
• Strong recurring revenue potential.
Risks:
• Still early-stage commercialisation – revenue ramp dependent on successful evaluations converting to full rollouts.
• Pharma adoption cycles are LONG (12–24 mths from evaluation to rollout).
August 10, 2025 at 12:24 AM
Positives:
• Strong recurring revenue potential.
Risks:
• Still early-stage commercialisation – revenue ramp dependent on successful evaluations converting to full rollouts.
• Pharma adoption cycles are LONG (12–24 mths from evaluation to rollout).
• Strong recurring revenue potential.
Risks:
• Still early-stage commercialisation – revenue ramp dependent on successful evaluations converting to full rollouts.
• Pharma adoption cycles are LONG (12–24 mths from evaluation to rollout).
It's had a good run.
Near term catalysts: Sept - product launch; late 2025 - sharing customer results; and hopefully some trial users might decide to buy more units for all their sites.
Weekly chart:
Near term catalysts: Sept - product launch; late 2025 - sharing customer results; and hopefully some trial users might decide to buy more units for all their sites.
Weekly chart:
August 10, 2025 at 12:22 AM
It's had a good run.
Near term catalysts: Sept - product launch; late 2025 - sharing customer results; and hopefully some trial users might decide to buy more units for all their sites.
Weekly chart:
Near term catalysts: Sept - product launch; late 2025 - sharing customer results; and hopefully some trial users might decide to buy more units for all their sites.
Weekly chart:
Sorry to hear this Ian, keep us posted.
August 6, 2025 at 11:08 AM
Sorry to hear this Ian, keep us posted.
Agree, fresh and earthy 🌲
July 29, 2025 at 1:46 AM
Agree, fresh and earthy 🌲